Clinical efficacy evaluation of first-in-class imipridone ONC201 in recurrent type II endometrial cancer
Ended Project Grant Awarded Last action
- Award ID
- R44CA221398
- Recipient
-
Oncoceutics, Inc. UEI ZKPGUP3MLBW9 Part of Chimerix, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,685,910
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Pennsylvania, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$33,409 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $777,000 | |
| Amendment | $714,000 | |
| Amendment | $4,319 | |
| Amendment | $0 | |
| Original award | $224,000 |
Show all 13
Quick answers
Who received award R44CA221398?
R44CA221398 was awarded to Oncoceutics, Inc. by National Cancer Institute (National Institutes of Health) on August 17, 2017.
How much is award R44CA221398 worth?
$1,685,910 has been obligated on R44CA221398.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award